NHS England Opens Enhertu Access for Advanced Breast Cancer
The NHS in England is making Enhertu available to about 1,000 patients a year with HER2-low advanced breast cancer after ministers reached a price agreement.
This article was automatically drafted and passed editorial compliance checks. It synthesizes public source metadata and is not a substitute for individual care or clinical review.
Patients in England with HER2-low advanced breast cancer can obtain Enhertu through the NHS from 17 September 2026. The change follows successful price negotiations led by ministers.
Who the NHS access covers
The NHS access applies to people in England with HER2-low advanced breast cancer. About 1,000 patients a year are expected to receive the drug under the arrangement.
How to interpret the survival figure
Enhertu is described as extending life by an average of seven months. That figure is a group average, not a forecast for an individual patient, so it does not establish how long any one person will benefit. A clinician must assess eligibility and the likely benefit for each patient.
MediIndex articles are for general information only and are not medical advice, diagnosis, or advertising. Outcomes vary by individual — consult a board-certified specialist for personal decisions.
